ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
21391401
|
126 |
28K |
10 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
126
|
28K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
21391401
|
179 |
28K |
14 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
179
|
28K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
21391401
|
179 |
28K |
3 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
179
|
28K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Professor Erin Howden Joins Race Oncology SAB
|
|
21391401
|
22 |
8.7K |
27 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
22
|
8.7K
|
27
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
21391401
|
971 |
226K |
7 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
971
|
226K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
21391401
|
971 |
226K |
9 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
971
|
226K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
21391401
|
197 |
48K |
4 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
197
|
48K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
21391401
|
971 |
226K |
7 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
971
|
226K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
21391401
|
304 |
71K |
7 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
304
|
71K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
21391401
|
323 |
71K |
11 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
323
|
71K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
21391401
|
323 |
71K |
3 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
323
|
71K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
21391401
|
323 |
71K |
3 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
323
|
71K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
21391401
|
323 |
71K |
4 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
323
|
71K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EGM Shareholder Presentation
|
|
21391401
|
45 |
12K |
3 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
45
|
12K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EGM Shareholder Presentation
|
|
21391401
|
45 |
12K |
11 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
45
|
12K
|
11
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Application for quotation of securities - RAC
|
|
21391401
|
16 |
4.3K |
21 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
16
|
4.3K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
21391401
|
323 |
71K |
15 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
323
|
71K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
21391401
|
111 |
33K |
12 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
111
|
33K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
21391401
|
430 |
102K |
9 |
26/01/24 |
26/01/24 |
ASX - By Stock
|
430
|
102K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
21391401
|
98 |
22K |
8 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
98
|
22K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
21391401
|
430 |
102K |
20 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
430
|
102K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Grants PharmAust Pre-IND Meeting
|
|
21391401
|
61 |
16K |
12 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
61
|
16K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Grants PharmAust Pre-IND Meeting
|
|
21391401
|
61 |
16K |
14 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
61
|
16K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
21391401
|
430 |
102K |
13 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
102K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at Emerging ASX Gems Conference
|
|
21391401
|
82 |
16K |
11 |
11/11/23 |
11/11/23 |
ASX - By Stock
|
82
|
16K
|
11
|
|
ASX - By Stock
|
HMD |
Company update
|
|
21391401
|
25 |
4.3K |
2 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
25
|
4.3K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
21391401
|
79 |
15K |
3 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
79
|
15K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
21391401
|
91 |
17K |
2 |
12/10/23 |
12/10/23 |
ASX - By Stock
|
91
|
17K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
21391401
|
106 |
20K |
5 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
20K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
21391401
|
106 |
20K |
0 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
20K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
21391401
|
106 |
20K |
0 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
20K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
8 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
380
|
80K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
21391401
|
132 |
32K |
2 |
18/09/23 |
18/09/23 |
ASX - By Stock
|
132
|
32K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
1 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
80K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Strategic Update August 2023
|
|
21391401
|
592 |
178K |
4 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
592
|
178K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
2 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
80K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
3 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
80K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
4 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
80K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
3 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
80K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
18 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
80K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
8 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
80K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
10 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
80K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
21391401
|
380 |
80K |
3 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
80K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
21391401
|
140 |
29K |
13 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
140
|
29K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
August , September , OPTOBER ,PAA
|
|
21391401
|
144 |
28K |
8 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
144
|
28K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
August , September , OPTOBER ,PAA
|
|
21391401
|
144 |
28K |
9 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
144
|
28K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
August , September , OPTOBER ,PAA
|
|
21391401
|
144 |
28K |
11 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
144
|
28K
|
11
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Quarterly Activities & Cashflow Report
|
|
21391401
|
9 |
2.2K |
1 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
9
|
2.2K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes 3rd Patient Cohort
|
|
21391401
|
48 |
10K |
4 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
48
|
10K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes 3rd Patient Cohort
|
|
21391401
|
48 |
10K |
3 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
48
|
10K
|
3
|
|